|
Active Motif and Swift Biosciences to advance
epigenetics
October 2016
SHARING OPTIONS:
ANN
ARBOR, Mich. & CARLSBAD, Calif.—Epigenetics-based research tools company Active Motif
Inc. has entered into a technology development partnership with Swift Biosciences, a leader
in sample and library preparation for next-generation sequencing (NGS). The two companies have partnered to deliver technical advancements in ChIP-Seq
workflow, a foundation application for epigenetics. The samples used in the ChIP-Seq workflow are often challenging because of their limited amounts. Swift
Biosciences has developed novel technologies that are said to enable the use of very low input samples and, when combined with Active Motif’s industry
leading ChIP-based technologies, the combination provides better sensitivity in detecting key protein-DNA interactions. The resulting combination of
technologies is reportedly allowing researchers to use 10 to 100 times less sample, using as little as 10pg of ChIP enriched samples.
“This is an important strategic partnership,” said Joseph Fernandez, CEO of Active Motif. “ChIP-Seq is a technically challenging
application where a major hurdle for researchers is generating good quality libraries from small amounts of starting material and the Swift
Biosciences’ technologies overcome many of these hurdles. By implementing these technologies into our R&D efforts, we have generated many impactful
advancements in our low cell ChIP programs and are now close to launching new, low cell ChIP-kits that will outperform anything else on the
market.”
“Epigenetics is one of the more challenging genetic fields and had seemed to hit a plateau
due to the limitations of sample inputs,” stated Dr. Timothy Harkins, president and CEO of Swift Biosciences. “One key technical advancement we
are introducing with Active Motif is our molecular indices to enable the unique barcoding of every DNA molecule within a sample, providing better signal
detection while utilizing more of their data. By working together to combine the best of our respective technologies, we are providing real advancements that
the broader community will be able to take as they continue to push how proteins and DNA interact.”
Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|